Floatz logo

13C-Fructose

Clear Cell Carcinoma

University of Texas Southwestern Medical CenterN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Clear Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Dana-Farber Cancer Institute
Phase 2B
Rucaparib
North Eastern German Society of Gynaecological Oncology
Phase 3B
Lorigerlimab
MacroGenics
Phase 2CCC
Dostarlimab
Yonsei University
Phase 2CCC
Inno-206
Yonsei University
Phase 2CCC

View all 20 →

Same molecule, other indications

13C-Fructose is also rated in:

kidney cancerDormant
D
Indicative ·
30 / 100
View asset →
urothelial carcinomaDormant
D
Indicative ·
30 / 100
View asset →
papillary renal cell carcinomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →